Healthcare · NYSE/NASDAQ: NVS
NOVARTIS AG
Drug Manufacturers - General
Market Cap $289.19B
Verdict: High
Quality Scores
Multi-Bagger
65/100
Compounder Quality
86/100
Management Credibility
86/100
Governance
78/100
Cash Flow Quality
92/100
AI Summary
Novartis AG (NVS) has successfully transformed from a diversified conglomerate into a focused, 'pure-play' innovative medicines powerhouse following the spin-offs of Alcon and Sandoz. This strategic pivot significantly improved operating margins and return on invested capital by shedding lower-margin, capital-intensive generic segments. The company maintains a robust R&D pipeline concentrated on high-value areas like oncology, immunology, and neuroscience. While top-line growth is often impacted by patent expiries (LOE), the underlying 'Core' operating income reflects high-quality operational…
Top Opportunities
- Successful transition to a high-margin Pure Play Innovative Medicines company
- Incredible FCF generation often exceeding 20% of revenue
- Progressive dividend policy with a 27-year streak of increases
Top Risks
- Significant revenue headwinds from multi-year patent cliffs
- Historical regulatory fines related to sales practices
- High reliance on Entresto and Cosentyx for core growth
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.